Cargando…
Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days after treat...
Autores principales: | Hoogland, Aasha I., Jayani, Reena V., Collier, Aaron, Irizarry‐Arroyo, Nathaly, Rodriguez, Yvelise, Jain, Michael D., Booth‐Jones, Margaret, Hyland, Kelly A., James, Brian W., Barata, Anna, Bachmeier, Christina A., Chavez, Julio C., Khimani, Farhad, Krivenko, Gabriel S., Lazaryan, Aleksandr, Liu, Hien D., Nishihori, Taiga, Pinilla‐Ibarz, Javier, Shah, Bijal D., Abidi, Muneer, Locke, Frederick L., Jim, Heather S. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957158/ https://www.ncbi.nlm.nih.gov/pubmed/33641257 http://dx.doi.org/10.1002/cam4.3664 |
Ejemplares similares
-
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
por: Logue, Jennifer M., et al.
Publicado: (2020) -
Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021) -
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
por: Riedell, Peter A., et al.
Publicado: (2020) -
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022) -
Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
por: Dean, Erin A., et al.
Publicado: (2023)